Supervisor：Ministry of Education of the People's Republic of ChinaSponsor：Sichuan University Editor-in-chief：ZHOU DONG Publishing period：
Bimonthly
ISSN：2096-0247CN：51-1762/R
Objective To explore the efficacy and safety of Perampanel (PER) monotherapy in children with focal epilepsy. Methods Forty-six children with focal epilepsy who were newly diagnosed in the Department of Neurology of Wuxi Children's Hospital and had not used anti-seizure medications during January 2021 to June 2022 were selected, including 24 males and 22 females, with an average age of (7.2 ± 2.4) years old. Mono-therapy of PER as the PER group (23 cases), mono-therapy of Levetiracetam (LEV) as the LEV group (23 cases). Compare the clinical efficacy and adverse reactions between the two groups. Result The total effective rate was 87.0% (20/23) in PER group and 73.9% (17/23) in LEV group after 3 months of treatment (P<0.05); the total effective rate in the PER group was 78.3% (18/23), and 60.9% (14/23) in the LEV group after 6 months of treatment (P<0.05). The differences were statistically significant. In the PER group, 2 children had adverse reactions, 1 case was lethargic, and 1 case was dizziness. By temporarily reducing the drug dose and slowing the rate of dosing, the adverse reactions disappeared. In LEV group, 3 children had adverse reactions, all of who were irritable in varying degrees. By slowing down the rate of drug addition, 2 children’s symptoms disappeared and 1 child's symptoms relieved during 3 ~ 6 months. Conclusion The new anti-seizure medication — PER has a better anti-epileptic effect on focal epilepsy, which is better than LEV. The adverse reactions of both drugs are less and mild, and can be selected according to clinical conditions.
Citation：CHEN Lilan, WANG Jianbiao, ZHOU Yineng, SUN Mingxia. Clinical efficacy of perampanel monotherapy in children with focal epilepsy. Journal of Epilepsy, 2023, 9(3): 192-194. doi: 10.7507/2096-0247.202303002Copy
Copyright ? the editorial department of Journal of Epilepsy of West China Medical Publisher. All rights reserved
1.
Devinsky O, Vezzani A, O'Brien TJ, et al. Epilepsy. Nature Reviews Disease Primers, 2018, 1: 27-31.
2.
Melchers NV, Mollenkopf S, Colebunders R, et al. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities. Infectious Diseases of Poverty, 2018, 7(1): 55-58.
3.
Carlson J M, Miller P A. Family burden, child disability, and the adjustment of mothers caring for children with epilepsy: Role of social support and coping. Epilepsy & Behavior, 2017, 68: 168-173.
4.
Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia, 2011, 52(7): 1331-1340.
5.
Jerry S, Tatum M, Leslie R. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Therapeutics & Clinical Risk Management, 2013, 56: 156-162.
6.
衛材 （中國） 藥業有限公司. 吡侖帕奈藥品說明書. 2021.
7.
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(4): 512-521.
8.
中國抗癲癇協會. 臨床診療指南: 癲癇病分冊. 人民衛生出版社, 2015.
9.
Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents, 2011, 11(2): 56-63.
10.
Potschka H. Perampanel: does it have broad-spectrum potential? Epilepsia, 2019, 60（Suppl 1）: 22-36.
11.
Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl, 2013, 127(s197): 3-8.
1. Devinsky O, Vezzani A, O'Brien TJ, et al. Epilepsy. Nature Reviews Disease Primers, 2018, 1: 27-31.
2. Melchers NV, Mollenkopf S, Colebunders R, et al. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities. Infectious Diseases of Poverty, 2018, 7(1): 55-58.
3. Carlson J M, Miller P A. Family burden, child disability, and the adjustment of mothers caring for children with epilepsy: Role of social support and coping. Epilepsy & Behavior, 2017, 68: 168-173.
4. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia, 2011, 52(7): 1331-1340.
5. Jerry S, Tatum M, Leslie R. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Therapeutics & Clinical Risk Management, 2013, 56: 156-162.
6. 衛材 （中國） 藥業有限公司. 吡侖帕奈藥品說明書. 2021.
7. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(4): 512-521.
8. 中國抗癲癇協會. 臨床診療指南: 癲癇病分冊. 人民衛生出版社, 2015.
9. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents, 2011, 11(2): 56-63.
10. Potschka H. Perampanel: does it have broad-spectrum potential? Epilepsia, 2019, 60（Suppl 1）: 22-36.
11. Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl, 2013, 127(s197): 3-8.
Click the content below to copy and paste a set citation format。
Citation：CHEN Lilan, WANG Jianbiao, ZHOU Yineng, SUN Mingxia. Clinical efficacy of perampanel monotherapy in children with focal epilepsy. Journal of Epilepsy, 2023, 9(3): 192-194. doi: 10.7507/2096-0247.202303002
1/5
WeChat